Visions - Summer 2009 - 8

(continued) Aside from the medical miracle it could provide, the financial burden on patients and their families could also be lessened, since the current medical cost of kidney dialysis per patient in the U.S. averages at $70,000 a year, with total cost in to U.S. patients of more than $30 billion a year. itself; Reata could be helped by bringing in a licensing partner. The Life Science Unit soon proceeded to secure meetings with Reata and seven Japanese pharmaceutical companies concerning distribution, with the meetings generating positive results. In his function as a facilitator,VP of Business Investment for SCOA and Director of Oxford Finance John Degen sees his engagement with Reata as a opportunity for SCOA to leverage the intellectual capital that Oxford has accumulated, and then offer new services to Oxford's customer base that are truly strategic in nature for all involved. “For Sumitomo as a whole, our initiative is to create new lines of business and incremental revenue for our Life Sciences business,” Degen said.“And at the same time, Reata has leveraged its borrowing relationship with Oxford for two additional key services: as a strategic partnering advisor for the Japanese market, and to act as a procurement and supply chain consultant in support of its drug manufacturing and development activities. Under this supply chain management, Reata can save millions of dollars in annual costs after RTA-402 goes into the market. I believe our efforts here will serve as a catalyst for other areas of the company to look within to create new revenue opportunities.” In the initial trials, RTA-402 has not only improved renal functions considerably, but could possibly reverse chronic kidney damage, giving it the potential to become a breakout treatment in this fight and a lifesaver for thousands of patients on dialysis and in need of liver transplants.Aside from the medical miracle it could provide, the financial burden on patients and their families could also be lessened, since the current medical cost of kidney dialysis per patient in the U.S. averages at $70,000 a year, with total cost in to U.S. patients of more than $30 billion a year. Reata will commence a larger clinical trial of RTA-402 soon, and if this trial goes well and the U.S. Food and Drug Administration grants approval, doctors could be administering the drug to CKD patients as early as 2012. For more information, please contact Yasunori Ishibashi at yasunori.ishibashi@sumitomocorp.com 8 visions Summer 2009

Table of Contents for the Digital Edition of Visions - Summer 2009

Contents
Visions - Summer 2009
The Power of Wind Meets The Power of Business
The Space Age Metal With Mettle
SCOA Synergy Helps Fight Kidney Disease on Two Fronts
Man's Best Friend Gets Relief From New Flea Product
The View From Washington
Visions - Summer 2009 - Visions - Summer 2009
Visions - Summer 2009 - 2
Visions - Summer 2009 - The Power of Wind Meets The Power of Business
Visions - Summer 2009 - 4
Visions - Summer 2009 - The Space Age Metal With Mettle
Visions - Summer 2009 - 6
Visions - Summer 2009 - SCOA Synergy Helps Fight Kidney Disease on Two Fronts
Visions - Summer 2009 - 8
Visions - Summer 2009 - Man's Best Friend Gets Relief From New Flea Product
Visions - Summer 2009 - 10
Visions - Summer 2009 - The View From Washington
Visions - Summer 2009 - 12
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fallwinter2019
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer2018
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winterspring2018
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall2017
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer2017
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winterspring2017
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall16
http://www.nxtbook.com/nxtbooks/sumitomo/visions-springsummer16
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter16
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall15
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer15
http://www.nxtbook.com/nxtbooks/sumitomo/visions-spring15
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter15
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summerfall14
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer14
http://www.nxtbook.com/nxtbooks/sumitomo/globalsolutions2014
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter14
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall13
http://www.nxtbook.com/nxtbooks/sumitomo/visions-springsummer13
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter13
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall12
http://www.nxtbook.com/nxtbooks/sumitomo/visions-springsummer12
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter12
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall11
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer11
http://www.nxtbook.com/nxtbooks/sumitomo/visions-spring11
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter11
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall10
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer10
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winterspring10
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall09
http://www.nxtbook.com/nxtbooks/sumitomo/visions-summer09
http://www.nxtbook.com/nxtbooks/sumitomo/visions-spring09
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter09
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall08
http://www.nxtbook.com/nxtbooks/sumitomo/visions-spring08
http://www.nxtbook.com/nxtbooks/sumitomo/visions-winter08
http://www.nxtbook.com/nxtbooks/sumitomo/visions-fall07
http://www.nxtbook.com/nxtbooks/sumitomo/vision-summer07
http://www.nxtbookMEDIA.com